Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Larisa V. Gubareva"'
Autor:
Vasiliy P, Mishin, Mira C, Patel, Anton, Chesnokov, Juan, De La Cruz, Ha T, Nguyen, Lori, Lollis, Erin, Hodges, Yunho, Jang, John, Barnes, Timothy, Uyeki, Charles T, Davis, David E, Wentworth, Larisa V, Gubareva
Publikováno v:
Emerging Infectious Diseases
Baloxavir showed broad-spectrum in vitro replication inhibition of 4 types of influenza viruses (90% effective concentration range 1.2–98.3 nmol/L); susceptibility pattern was influenza A ˃ B ˃ C ˃ D. This drug also inhibited influenza A viruses
Autor:
Larisa V. Gubareva, Katrina Sleeman, Amanda Balish, Vasiliy P. Mishin, Rebecca Garten, Alicia M. Fry, Julie Villanueva, Zhu Guo, James Stevens
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:2045-2051
Since 2011, outbreaks caused by influenza A(H3N2) variant [A(H3N2)v] viruses have become a public health concern in the United States. The A(H3N2)v viruses share the A(H1N1)pdm09 M gene containing the marker of M2 blocker resistance, S31N, but do not
Autor:
James Stevens, Vasiliy P. Mishin, Paul J. Carney, Katrina Sleeman, Larisa V. Gubareva, Marnie Levine
Publikováno v:
Antiviral Research. 101:93-96
Propagation of influenza A(H3N2) viruses in MDCK cells has been associated with the emergence of neuraminidase (NA) variants carrying a change at residue 151. In this study, the pyrosequencing assay revealed that ∼90% of A(H3N2) virus isolates anal
Autor:
Jianzhu Chen, Alexander M. Klibanov, Larisa V. Gubareva, Terrence M. Tumpey, Luis Álvarez de Cienfuegos, Alisha K. Weight, Jayanta Haldar
Publikováno v:
PMC
Effects of the commercial drug zanamivir (Relenza™) covalently attached to poly-l-glutamine on the infectivity of influenza A viruses are examined using the plaque reduction assay and binding affinity to viral neuraminidase (NA). These multivalent
Autor:
Michael W. Shaw, Rebecca Garten, Larisa V. Gubareva, Alexander Klimov, Margaret Okomo-Adhiambo, Vasiliy P. Mishin, Tiffany G. Sheu, Varough M. Deyde, Ha T. Nguyen, A. Angelica Trujillo, Alicia M. Fry, Katrina Sleeman
Publikováno v:
Antiviral Therapy. 15:1151-1159
Background Antiviral drugs are an important option for managing infections caused by influenza viruses. This study assessed the drug susceptibility of 2009 pandemic influenza A (H1N1) viruses collected globally between April 2009 and January 2010. Me
Publikováno v:
Antimicrobial Agents and Chemotherapy. 54:3671-3677
The neuraminidase inhibitors (NAIs) zanamivir and oseltamivir are currently the only antiviral drugs effective for the treatment and prophylaxis of 2009 pandemic influenza A (H1N1) virus infections. The proven potential of these viruses to acquire NA
Autor:
Rebecca Garten, Ha T. Nguyen, Tiffany G. Sheu, Varough M. Deyde, Alexander Klimov, Katrina Sleeman, Margaret Okomo-Adhiambo, Xiyan Xu, Michael W. Shaw, Larisa V. Gubareva
Publikováno v:
Antiviral Research. 85:381-388
The neuraminidase inhibitors (NAIs), oseltamivir and zanamivir, are essential for treatment and prevention of influenza A and B infections. Oseltamivir resistance among influenza A (H1N1) viruses rapidly emerged and spread globally during the 2007-20
Autor:
Novikov Dv, Larisa V. Gubareva, Frederick G. Hayden, Marina S. Nedyalkova, Erich Hoffmann, K. Gopal Murti
Publikováno v:
Journal of General Virology. 83:2683-2692
Both influenza A virus surface glycoproteins, the haemagglutinin (HA) and neuraminidase (NA), interact with neuraminic acid-containing receptors. The influenza virus A/Charlottesville/31/95 (H1N1) has shown a substantially reduced sensitivity to NA i
Autor:
Margaret Okomo-Adhiambo, Larisa V. Gubareva, Katrina Sleeman, Zhu Guo, Ha T. Nguyen, Xiyan Xu, James Stevens, Hua Yang, Vasiliy P. Mishin, Marnie Levine, Daisuke Tamura
Publikováno v:
Antimicrobial agents and chemotherapy. 57(12)
Assessment of drug susceptibility has become an integral part of influenza virus surveillance. In this study, we describe the drug resistance profile of influenza A(H3N2) virus, A/Mississippi/05/2011, collected from a patient treated with oseltamivir
Autor:
Mikhail Matrosovich, Robert G. Webster, Richard C. Bethell, Malcolm K. Brenner, Larisa V. Gubareva
Publikováno v:
The Journal of Infectious Diseases. 178:1257-1262
Zanamivir, a neuraminidase inhibitor, has shown promise as a drug to control influenza. During prolonged treatment with zanamivir, a mutant virus was isolated from an immunocompromised child infected with influenza B virus. A hemagglutinin mutation (